Periodic Reporting for period 1 - SynVaccine (Rational Design and Construction of Viral Based Products)
Reporting period: 2017-06-01 to 2017-09-30
The overall objectives is to investigate the feasibility of commercialising derived products from SynVaccine's proprietary technology SynRAD. And the the most feasible pathway of entrance
The importance of first addressing the Animal Health market segment, due to the ability to sell direct to veterinary physicians, farmers, and even household pet owners as a distinctive pull factor in a pharmaceutical industrial roadmap already crowded with regulatory hurdles. This being in direct contrast to tougher price negotiations with governments and insurers in order to sell solutions in human healthcare, as major push factors. The core concern of developmental cost being slashed significantly in Animal Health in comparison to clinical applications – due to less onerous trials, as well as Animal Health products having greater proprietary longevity and less competition on each target application. This further supports our strategy to expedite early monetary returns to our company due to the costly nature of drug development; especially so for a non-manufacturing proprietary technology provider.